| Purpose of the guideline: |
Dilated cardiomyopathy (DCM) is a heterogeneous cardiomyopathy characterized by ventricular enlargement and decreased myocardial contractile function. Prolonged ventricular enlargement leads to decreased ventricular function and heart failure, followed by conduction system abnormalities, ventricular arrhythmias, thromboembolism, and even sudden death. The incidence rate of this disease in China is 13 to 84 per 100000 people, and the familial ones account for 2.25 to 8.8%. The 52 month mortality rate is 42.24%. In recent years, clinical evidence has shown that the combination of traditional Chinese and Western medicine in the treatment of DCM has played an important role in improving clinical symptoms, reversing ventricular remodeling, improving myocardial energy metabolism, enhancing immune regulation, reducing mortality and readmission rates. These studies are increasingly being used to guide clinical practice. Due to the lack of expert consensus or clinical application guidelines for the integrated diagnosis and treatment of DCM in China, the development process of guidelines based on the World Health Organization Guidelines and the GRADE methodology for the integrated diagnosis and treatment of dilated cardiomyopathy is of great significance for improving the level of prevention and treatment of cardiovascular diseases. This guide closely combines the current medical situation and health economic needs in China, recommends the collaborative treatment methods of traditional Chinese medicine and Western medicine for DCM, recommends different treatment plans for DCM patients with different syndrome types, reflects the dynamic diagnosis and treatment model of disease syndrome integration, focuses on common complications, and leverages the advantages of integrated intervention of traditional Chinese and Western medicine. It recommends treatment methods with certain evidence or high consensus, providing clinical doctors with safe and effective treatment methods, which have good applicability, economy, and clinical operability. |
